WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Fermer ce répertoireKeratoplastic and keratolytic agents
Afficher le documentBenzoyl peroxide
Afficher le documentCoal tar
Afficher le documentDithranol
Afficher le documentSalicylic acid
Afficher le documentTretinoin
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Tretinoin

Cream, 0.025-0.1%

General information

Tretinoin is the acid form of retinol. It is used topically in the treatment of acne. It is a keratolytic agent that reduces follicular hyperkeratosis by stimulating the turnover of epithelial cells. It is not significantly absorbed following topical application.

Clinical information

Uses

Treatment of mild to moderate acne vulgaris, especially in patients with a comedonal component.

Dosage and administration

The cream formulations cause less irritation than the gels. Treatment is usually started with the lowest-strength (0.025%) cream formulation. The strength can be increased as tolerance develops, to a maximum of 0.1%.

Adults and adolescents: a thin layer of cream should be applied to the affected areas once or twice daily, 30 minutes after washing. A therapeutic response characterized by redness and scaling occurs within 3-6 weeks. Treatment is usually continued for at least 3 months.

Contraindications

Hypersensitivity to tretinoin.

Use in pregnancy

The low blood levels that result from topically applied tretinoin have not been associated with an increase in fetal malformations. However, tretinoin should be used in women of child-bearing age only if the potential benefits outweigh the possible risks.

Precautions

Care should be taken to avoid contact with the eyes, mucous membranes and open sores. Tretinoin may produce severe irritation of the skin in patients with eczema. Exposure to ultraviolet light increases the intensity of the inflammatory reaction.

Adverse effects

Reversible local inflammatory reactions occur. Redness and scaling of the skin are necessary for a therapeutic response, but if severe erythema, blistering or crusting of the skin occurs, a lower-strength formulation should be used.

Drug interactions

Concomitant use of other topical medications for acne should be avoided. Medicated soaps and topical lotions containing high concentrations of alcohol should be avoided, since they may cause stinging of treated skin.

Storage

Cream should be stored in tightly closed containers, protected from light.

 

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019